CN102579172A - Drug-coating stent - Google Patents
Drug-coating stent Download PDFInfo
- Publication number
- CN102579172A CN102579172A CN2012100340362A CN201210034036A CN102579172A CN 102579172 A CN102579172 A CN 102579172A CN 2012100340362 A CN2012100340362 A CN 2012100340362A CN 201210034036 A CN201210034036 A CN 201210034036A CN 102579172 A CN102579172 A CN 102579172A
- Authority
- CN
- China
- Prior art keywords
- stent
- drug
- coating
- medicine
- coating stent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention provides a drug-coating stent which is an effective intervention apparatus for treating cerebrovascular and cardiovascular stenosis or obstruction. After implantation of the drug-coating stent into the blood vessel, under the one-way scouring of blood flow, a releasing speed and a distribution rule of medicinal components are influenced by the local blood flow dynamic environment. If the stent is designed as the existing drug-coating stent, i.e., uniform distribution and release of drug on the stent, an unbalanced drug concentration in stent, drug concentration gradually increases from front end to rear end, will be inevitably caused, so that the effects of the drug-coating stent will finally be influenced. The invention discloses the novel drug-coating stent with the drug concentration in coating gradually decreased from front end to rear end, in this way, in spite of blood flow scouring action after implantation of the stent into blood vessel, basically balanced drug concentration in the axial direction inside stent can be kept.
Description
Technical field
The present invention relates to a kind of coating stent of medicine
Background technology
Cardiovascular and cerebrovascular disease is a kind of disease of serious threat human health, and sickness rate and fatality rate are all very high.A kind of effective ways of treatment cardiovascular disease are to carry out support through Wicresoft's intervention means to implant at present, make blood vessel narrow or that stop up unimpeded again, recover blood supply.First generation intravascular stent is a bare metal stent, though this support can realize dredging the purpose of narrow or artery-clogging, untoward reaction such as the thrombosis after implanting, vascellum endometrial hyperplasia are following, and anaphase effect is relatively poor.Second filial generation intravascular stent subsequently: coating stent of medicine (Drug eluting stent, birth DES) has suppressed these untoward reaction to a great extent, and clinical effectiveness is better.So-called coating stent of medicine; Promptly outside intravascular stent, apply one deck and combine the polymer coating of effective ingredient; This medication coat will discharge pharmaceutical compositions in support is implanted the back a very long time; Neointimal hyperplasia or thrombosis in prevention, the inhibition support, thus prevent in-stent restenosis, reach the purpose that keeps long-term patency rates.
Receive washing away of unidirectional blood flow behind the coating stent of medicine implantable intravascular, the rate of release of ingredient and the regularity of distribution can receive the influence of the partial hemodynamics environment of blood vessel.If according to the design (medicine is uniform distribution and release on support) of existing coating stent of medicine, must cause the unbalanced of the interior drug level of support: drug level raises gradually to the rear end from front end.The final action effect that influences coating stent of medicine.
Summary of the invention
The present invention is directed to the uneven technical problem of coating stent of medicine internal drug CONCENTRATION DISTRIBUTION; A kind of new coating stent of medicine is proposed; Make support internal drug concentration behind implantable intravascular keep more uniform distribution; Thereby it is low to solve coating stent of medicine Inner Front End drug level, the problem that the rear end drug level is high.
In order to solve the problems of the technologies described above, the present invention realizes through following technical scheme: a kind of novel medicament coating bracket, this coating stent of medicine has the branch of front-end and back-end, and drug level reduces gradually on the medication coat of front end to rear end.
Said coating stent of medicine comprises holder part and medication coat part.
The holder part of said coating stent of medicine can be that metal rack also can be the degradation material support.
The weaving manner of said coating stent of medicine can adopt the weaving manner of any existing intravascular stent.
Said medication coat is formed by polymer with by the ingredient of polymer overmold.
Said ingredient is the combination of a kind of or 2-4 kind in statins, rapamycin class, taxanes, the heparin class medicine.
Pass through technique scheme; Under the blood flow mobilization toward the rear end from the coating stent of medicine front end; The approximate uniform distribution that can keep drug level in the coating stent of medicine implantable intravascular after-poppet improves the performance that coating stent of medicine suppresses pathological changes such as in-stent restenosis, vascellum endometrial hyperplasia better.
Description of drawings:
Fig. 1 is a front view of the present invention;
Fig. 2 is used for explaining that the present invention's drug level vertically distributes.
Among the figure: 1 coating stent of medicine front end; 2 coating stent of medicine main bodys; 3 coating stent of medicine rear ends.
Specific embodiments
The specific embodiment of the present invention is explained as follows:
As shown in Figure 1, coating stent of medicine disclosed by the invention has the shape of intravascular stent, and it is made up of the two large divisions: holder part and medication coat part.Wherein holder part can be metal rack or biodegradable stent, and its weaving manner shape in other words can adopt the form of presentation or the shape of disclosed intravascular stent before.The medication coat part is made up of two parts again: polymer and ingredient.Wherein polymer can adopt the component of polymer on disclosed coating stent of medicine surface, and ingredient is the combination of a kind of or 2-4 kind in statins, rapamycin class, taxanes, the heparin class medicine.Maximum characteristics of the present invention are presented as: to the rear end, drug level reduces gradually from the front end of coating stent of medicine, and the drug level of rearmost end is minimum or is zero.The drug concentrations regularity of distribution can be as shown in Figure 2 the linear distribution rule.To the release rule of different pharmaceutical, also can make amendment, but keep from the front end characteristics that drug level reduces gradually to the rear end to the regularity of distribution.
When the doctor carries out implant procedure, keep the support front end to flow into holder orientation at blood flow, holder orientation is flowed out at blood flow in the rear end.After the implantation, in the time of drug release on the coating stent of medicine, though the drug level on the support is different, under the blood flow mobilization toward the rear end from front end, drug level is tending towards uniform distribution in the support.
Claims (5)
1. a coating stent of medicine comprises holder part and applies superincumbent medication coat, it is characterized in that said coating stent of medicine has the branch of front-end and back-end, and drug level reduces gradually on the medication coat of front end to rear end.
2. coating stent of medicine according to claim 1 is characterized in that, said coating stent of medicine comprises holder part and medication coat part.
3. coating stent of medicine according to claim 1 is characterized in that, the holder part of said coating stent of medicine can be that metal rack also can be the degradation material support.
4. coating stent of medicine according to claim 1 is characterized in that, said medication coat is formed by polymer with by the ingredient of polymer overmold.
5. coating stent of medicine according to claim 1 is characterized in that, said ingredient is the combination of a kind of or 2-4 kind in statins, rapamycin class, taxanes, the heparin class medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100340362A CN102579172A (en) | 2012-02-15 | 2012-02-15 | Drug-coating stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100340362A CN102579172A (en) | 2012-02-15 | 2012-02-15 | Drug-coating stent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102579172A true CN102579172A (en) | 2012-07-18 |
Family
ID=46468795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100340362A Pending CN102579172A (en) | 2012-02-15 | 2012-02-15 | Drug-coating stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102579172A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050064005A1 (en) * | 2003-08-13 | 2005-03-24 | Dinh Thomas Q. | Active agent delivery systems including a miscible polymer blend, medical devices, and methods |
| CN1812755A (en) * | 2003-06-23 | 2006-08-02 | 比奥特罗尼克有限及两合公司 | Stent comprising a coating system |
| CN101185779A (en) * | 2007-12-19 | 2008-05-28 | 上海赢生医疗科技有限公司 | Method for preparing medicine sustained-releasing bracket |
| CN101313873A (en) * | 2007-05-31 | 2008-12-03 | 乐普（北京）医疗器械股份有限公司 | Biology polypeptide medicament blood vessel bracket and preparation method thereof |
| CN101513540A (en) * | 2008-02-18 | 2009-08-26 | 龙脉医疗器械(北京)有限公司 | Drug-eluting coronary artery stent and method for preparing same |
| US20110153005A1 (en) * | 2009-12-21 | 2011-06-23 | Claus Harder | Medical implant, coating method and implantation method |
| CN102283727A (en) * | 2011-06-23 | 2011-12-21 | 北京航空航天大学 | Hole-type medicine coating bracket |
-
2012
- 2012-02-15 CN CN2012100340362A patent/CN102579172A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1812755A (en) * | 2003-06-23 | 2006-08-02 | 比奥特罗尼克有限及两合公司 | Stent comprising a coating system |
| US20050064005A1 (en) * | 2003-08-13 | 2005-03-24 | Dinh Thomas Q. | Active agent delivery systems including a miscible polymer blend, medical devices, and methods |
| CN101313873A (en) * | 2007-05-31 | 2008-12-03 | 乐普（北京）医疗器械股份有限公司 | Biology polypeptide medicament blood vessel bracket and preparation method thereof |
| CN101185779A (en) * | 2007-12-19 | 2008-05-28 | 上海赢生医疗科技有限公司 | Method for preparing medicine sustained-releasing bracket |
| CN101513540A (en) * | 2008-02-18 | 2009-08-26 | 龙脉医疗器械(北京)有限公司 | Drug-eluting coronary artery stent and method for preparing same |
| US20110153005A1 (en) * | 2009-12-21 | 2011-06-23 | Claus Harder | Medical implant, coating method and implantation method |
| CN102283727A (en) * | 2011-06-23 | 2011-12-21 | 北京航空航天大学 | Hole-type medicine coating bracket |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Roy-Chaudhury et al. | Hemodialysis vascular access dysfunction: from pathophysiology to novel therapies | |
| Farooq et al. | Restenosis: delineating the numerous causes of drug-eluting stent restenosis | |
| Ma et al. | Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies | |
| CA2636336A1 (en) | Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions | |
| ATE521309T1 (en) | STENT FOR DELIVERING A THERAPEUTIC AGENT FROM A SIDE SURFACE OF A STENT STRUT | |
| Jackson et al. | A review of the coronary applications of the drug coated balloon | |
| EP2272550A3 (en) | Rapamycin reservoir eluting stent | |
| Kwon et al. | Functional self-expandable metal stents in biliary obstruction | |
| AU2013338051A1 (en) | Polymer coating compositions and coated products | |
| WO2004110302A3 (en) | Methods of delivering anti-restenotic agents from a stent | |
| CO6491121A2 (en) | SEEDS FOR BRAQUITERAPY WITH QUICK DISSOLVING MATRIX FOR AN OPTIMAL SUPPLY OF RADIONUCLEID TO CANCEROSE TISSUE | |
| MX339125B (en) | Bare metal stent with drug eluting reservoirs. | |
| WO2008086490A3 (en) | Multiple drug-eluting coronary artery stent for percutaneous coronary artery intervention | |
| Zhang et al. | Multistep instead of one-step: a versatile and multifunctional coating platform for biocompatible corrosion protection | |
| Anisimova et al. | Anti-tumour activity of Mg-6% Ag and Mg-10% Gd alloys in mice with inoculated melanoma | |
| Baek et al. | Reduced restenosis and enhanced re-endothelialization of functional biodegradable vascular scaffolds by everolimus and magnesium hydroxide | |
| Jia et al. | A novel polymer‐free paclitaxel‐eluting stent with a nanoporous surface for rapid endothelialization and inhibition of intimal hyperplasia: Comparison with a polymer‐based sirolimus‐eluting stent and bare metal stent in a porcine model | |
| CN104107459A (en) | Degradable polymer coating support with sequential response function, and making method thereof | |
| WO2007092833A3 (en) | Drug delivery stent with extended in vivo drug release | |
| WO2016178251A3 (en) | Drug eluting bioresorbable polymer mesh covered embolic protection implantable device | |
| WO2010042343A3 (en) | Combination local delivery using a stent | |
| CN102579172A (en) | Drug-coating stent | |
| CN103990186B (en) | A kind of have support of control restenosis medicaments coating and preparation method thereof | |
| RU2013127579A (en) | LOCAL VASCULAR DELIVERY OF A2A ADENOSINE RECEPTOR AGONISTS TO REDUCE MYOCARDIAL DAMAGE | |
| Banning et al. | Drug-eluting balloons: what is their place on the interventionalist's shelf? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120718 |